Multicentre, phase II study of gemcitabine and S‐1 in patients with advanced biliary tract cancer: TG1308 study

BACKGROUND & AIMS: Gemcitabine plus cisplatin (GC) remains the standard, frontline therapy for advanced biliary tract cancer (ABTC). The JCOG1113 study suggested that gemcitabine plus S‐1 (GS) had noninferior median overall survival and comparable incidence of significant neutropenia as compared...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Liver Int
Main Authors: Chiang, Nai‐Jung, Chen, Ming‐Huang, Yang, Shih‐Hung, Hsu, Chiun, Yen, Chia‐Jui, Tsou, Hsiao‐Hui, Su, Yung‐Yeh, Chen, Jen‐Shi, Shan, Yan‐Shen, Chen, Li‐Tzong
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Liver Cancer
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540301/
https://ncbi.nlm.nih.gov/pubmed/32463975
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/liv.14538
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados